ATE422352T1 - Liposomaler grippeimpfstoff und verfahren - Google Patents

Liposomaler grippeimpfstoff und verfahren

Info

Publication number
ATE422352T1
ATE422352T1 AT97927355T AT97927355T ATE422352T1 AT E422352 T1 ATE422352 T1 AT E422352T1 AT 97927355 T AT97927355 T AT 97927355T AT 97927355 T AT97927355 T AT 97927355T AT E422352 T1 ATE422352 T1 AT E422352T1
Authority
AT
Austria
Prior art keywords
methods
liposomal
flu vaccine
vaccines
influenza
Prior art date
Application number
AT97927355T
Other languages
German (de)
English (en)
Inventor
Eliezer Kedar
Ilan Babai
Yechezkel Barenholz
Original Assignee
Yissum Res Dev Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co filed Critical Yissum Res Dev Co
Application granted granted Critical
Publication of ATE422352T1 publication Critical patent/ATE422352T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • A61K2039/55533—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S436/00—Chemistry: analytical and immunological testing
    • Y10S436/829—Liposomes, e.g. encapsulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT97927355T 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren ATE422352T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2006396P 1996-06-24 1996-06-24

Publications (1)

Publication Number Publication Date
ATE422352T1 true ATE422352T1 (de) 2009-02-15

Family

ID=21796541

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97927355T ATE422352T1 (de) 1996-06-24 1997-06-24 Liposomaler grippeimpfstoff und verfahren

Country Status (8)

Country Link
US (1) US5919480A (esLanguage)
EP (1) EP0954286B1 (esLanguage)
JP (2) JP4227195B2 (esLanguage)
AT (1) ATE422352T1 (esLanguage)
AU (1) AU731705B2 (esLanguage)
CA (1) CA2258878C (esLanguage)
DE (1) DE69739253D1 (esLanguage)
WO (1) WO1997049423A2 (esLanguage)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731972B1 (en) * 2000-02-04 2010-06-08 Vlaams Interuniversitair Instituut Voor Biotechnologie Immunoprotective influenza antigen and its use in vaccination
JP2001521908A (ja) * 1997-10-31 2001-11-13 シストロン バイオテクノロジー インク． ワクチンアジュバントとして有用な封入された免疫調節物質
AT407958B (de) 1999-02-11 2001-07-25 Immuno Ag Inaktivierte influenza-virus-vakzine zur nasalen oder oralen applikation
CA2428103C (en) 2000-11-07 2015-06-09 Immunovaccine Technologies Inc. Vaccines with enhanced immune response and methods for their preparation
AU2002236526B9 (en) * 2000-11-15 2008-05-01 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Sol-fusin: use of GP64-6His to catalyze membrane fusion
MY134424A (en) * 2001-05-30 2007-12-31 Saechsisches Serumwerk Stable influenza virus preparations with low or no amount of thiomersal
CA2451091A1 (en) * 2001-06-25 2003-01-03 Yissum Research Development Company Of The Hebrew University In Jerusale M A method for preparation of vesicles loaded with biological material and different uses thereof
EP1401492B1 (en) * 2001-07-05 2009-05-20 LTB4 Sweden AB Ltb4 as vaccine adjuvant
US20040208920A1 (en) * 2002-07-03 2004-10-21 Dov Michaeli Liposomal vaccine
US20040247661A1 (en) * 2002-07-03 2004-12-09 Dov Michaeli Liposomal vaccine
US20050169979A1 (en) * 2002-07-03 2005-08-04 Dov Michaeli Liposomal vaccine
CN1812766A (zh) 2003-04-25 2006-08-02 宾州研究基金会 用于全身传递使生长停滞的、衍生于脂质的生物活性化合物的方法和系统
US20060286161A1 (en) * 2003-05-09 2006-12-21 Steffen Panzner Injectable liposomal depots for delivering active ingredients
RU2390351C2 (ru) * 2003-08-11 2010-05-27 Дзе Ресерч Фаундейшн Фо Макробайал Дизизес Оф Осака Юниверсити Вакцина против вируса гриппа для введения через слизистую и способ предотвращения гриппа
CN102172397B (zh) * 2003-08-21 2013-01-30 利普泰克有限公司 树突细胞的体内靶向
FR2868951B1 (fr) * 2004-04-15 2006-07-21 Ethypharm Sa Compositions contenant ds vesicules lamellaires incorporant un principe actif peu soluble dans l'eau et produits intermediaires utiles pour leur preparation
US20050260260A1 (en) * 2004-05-19 2005-11-24 Edward Kisak Liposome compositions for the delivery of macromolecules
KR20070108371A (ko) * 2005-01-05 2007-11-09 필라델피아 헬스 앤드 에듀케이션 코퍼레이션 전달 비히클, 생물활성 물질 및 바이러스 백신
CA2523032A1 (en) 2005-10-07 2007-04-07 Immunovaccine Technologies Inc. Vaccines for cancer therapy
WO2009039628A1 (en) * 2007-09-27 2009-04-02 Immunovaccine Technologies Inc. Use of liposomes in a carrier comprising a continuous hydrophobic phase for delivery of polynucleotides in vivo
US20100209452A1 (en) * 2007-10-03 2010-08-19 Immunovaccine Technologies, Inc Compositions comprising an antigen, an amphipathic compound and a hydrophobic carrier, and uses thereof
EP2231180B1 (en) * 2008-01-16 2016-08-17 Ben-gurion University Of The Negev Research And Development Authority Vaccine for alzheimer's disease
AU2009253780B2 (en) 2008-06-05 2014-08-14 Immunovaccine Technologies Inc. Compositions comprising liposomes, an antigen, a polynucleotide and a carrier comprising a continuous phase of a hydrophobic substance
CA2730340C (en) * 2008-07-14 2017-02-07 Polypid Ltd. Sustained-release drug carrier composition
US20120157419A1 (en) 2009-02-02 2012-06-21 Tuvia Gilat Methods and compositions for treating alzheimer's disease
ES2573427T3 (es) 2009-07-06 2016-06-07 Variation Biotechnologies Inc. Procedimientos para preparar vesículas y formulaciones producidas a partir de las mismas
CA2803282C (en) 2009-07-06 2018-05-01 David E. Anderson Methods for preparing vesicles and formulations produced therefrom
AU2010272167B2 (en) 2009-07-14 2016-11-17 Polypid Ltd. Sustained-release drug carrier composition
EP2485758A1 (en) 2009-10-09 2012-08-15 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
CA2783001C (en) 2010-01-19 2017-12-12 Polypid Ltd. Sustained-release nucleic acid matrix compositions
JP6119030B2 (ja) * 2010-07-06 2017-04-26 ヴァリエーション バイオテクノロジーズ インコーポレイテッド インフルエンザを治療するための組成物及び方法
CN107296792B (zh) 2011-01-13 2021-07-27 变异生物技术公司 囊泡及由其产生之制剂的制备方法
EP2663327A4 (en) 2011-01-13 2015-12-02 Variation Biotechnologies Inc COMPOSITIONS AND METHOD FOR THE TREATMENT OF VIRUS INFECTIONS
CA2850857C (en) 2011-10-06 2022-07-26 Immunovaccine Technologies Inc. Liposome compositions comprising an adjuvant that activates or increases the activity of tlr2 and uses thereof
WO2013072768A2 (en) 2011-11-18 2013-05-23 Variation Biotechnologies, Inc. Synthetic derivatives of mpl and uses thereof
US20140356399A1 (en) 2012-01-12 2014-12-04 Variation Biotechnologies, Inc. Compositions and methods for treating viral infections
CA2894467A1 (en) 2012-01-27 2013-08-01 Variation Biotechnologies Inc. Methods for preparing thermostable compositions comprising a lipid component and thermolabile therapeutic agents
CN103736090B (zh) * 2014-01-27 2016-03-02 中国医学科学院医学生物学研究所 甲磺酸去铁胺佐剂及含甲磺酸去铁胺佐剂的疫苗
CN110151702A (zh) * 2019-06-24 2019-08-23 昆明医科大学 聚乙二醇修饰流感疫苗脂质体及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117113A (en) * 1974-06-25 1978-09-26 National Research Development Corporation Immunological preparations
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4235877A (en) * 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4534899A (en) 1981-07-20 1985-08-13 Lipid Specialties, Inc. Synthetic phospholipid compounds
US4426330A (en) 1981-07-20 1984-01-17 Lipid Specialties, Inc. Synthetic phospholipid compounds
JPH0720857B2 (ja) * 1988-08-11 1995-03-08 テルモ株式会社 リポソームおよびその製法
AU631377B2 (en) * 1988-08-25 1992-11-26 Liposome Company, Inc., The Affinity associated vaccine
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
JP3037994B2 (ja) * 1989-11-02 2000-05-08 テルモ株式会社 リポソーム表面への蛋白質吸着抑制剤
JP3220180B2 (ja) * 1991-05-23 2001-10-22 三菱化学株式会社 薬剤含有タンパク質結合リポソーム
AU4662393A (en) * 1992-07-08 1994-01-31 Schering Corporation Use of gm-csf as a vaccine adjuvant
US6326353B1 (en) * 1993-03-23 2001-12-04 Sequus Pharmaceuticals, Inc. Enhanced circulation effector composition and method
CA2168671C (en) * 1993-08-06 2007-04-10 Yechezkel Barenholz A method for high loading of vesicles with biopolymeric substances
AUPM500494A0 (en) * 1994-04-12 1994-05-05 Minister For Agriculture & Rural Affairs For The State Of New South Wales, The Composition for use in increasing mucosal immunity

Also Published As

Publication number Publication date
CA2258878C (en) 2008-03-18
DE69739253D1 (de) 2009-03-26
EP0954286B1 (en) 2009-02-11
WO1997049423A2 (en) 1997-12-31
JP2008260779A (ja) 2008-10-30
CA2258878A1 (en) 1997-12-31
AU3188297A (en) 1998-01-14
US5919480A (en) 1999-07-06
AU731705B2 (en) 2001-04-05
JP2000513352A (ja) 2000-10-10
EP0954286A2 (en) 1999-11-10
JP4227195B2 (ja) 2009-02-18
WO1997049423A3 (en) 1998-02-19

Similar Documents

Publication Publication Date Title
ATE422352T1 (de) Liposomaler grippeimpfstoff und verfahren
NO20001768D0 (no) Viruskapsomervaksine, fremgangsmåte til fremstilling samt anvendelse derav
IS4518A (is) Nýtt lyfjaform fyrir bóluefni
EP1955709A3 (en) Adjuvant compositions for enhancing immune responses to polynucleotide-based vaccines
DE69929444D1 (de) Cpg-zusammensetzungen, saponin-adjuvantien und verfahren zu deren verwendung
DE69533594D1 (de) Präparate und verfahren zum auslösen von ctl-immunität
IL150602A (en) Proteosome influenza vaccine, method for preparing such and use thereof
FI953608L (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalvossa järjestelmällisellä rokottamisella
EP1964573A3 (en) Method of inducing and/or enhancing an immune response to tumor antigens
BG101995A (en) Saponin and sterol-containing vaccines
EP2368575A3 (en) Dry formulation for transcutaneous immunization
DE68921389D1 (de) Influenzaimpfstoff und Adjuvanten.
WO1999002183A3 (en) A method of inducing a ctl response
WO2001034801A3 (en) Recombinant gelatin in vaccines
FI955667A0 (fi) Adjuvantteja RS-viruksen vastaisia rokotteita varten
NZ331651A (en) BSW17 peptide immunogens for vaccination against and treatment of allergy
EP1162272A3 (en) Generation of immune responses to prostate-specific antigen (SPA)
BR9506885A (pt) Vacinas contendo vesículas de lipidio paucilamelares como adjuvantes imunológicos
ES2177927T3 (es) Composicion para provocar una reaccion inmunologica a un determinante antigenico no proteinico.
WO2002076485A3 (en) Vaccine for modulating between t1 and t2 immune responses
DE69637435D1 (de) Saponin-zusammensetzungen und deren verwendung
CA2133108A1 (en) Pasteurella haemolytica type a-1 bacterin-toxoid vaccine
DE69433760D1 (de) Gegen mumps impfstoff, das ein virus des jeryl-lynn stammes enthält
EP0320034A3 (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
FR2698271B1 (fr) Vaccin contre le virus de la leucémie bovine, nouveau peptide immunogène et kit de vaccination.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties